NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT03363763 2025-12-01
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Aucta Pharmaceuticals, Inc
Phase 2 Terminated
NCT06399029 2025-11-19
TRUX-LST
University of Zurich
Phase 2 Recruiting
NCT01880515 2025-05-11
Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT05966584 2024-08-29
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03440515 2020-01-07
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Completed
NCT02239731 2018-02-27
Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
Vyne Therapeutics Inc.
Phase 2 Completed
NCT00473083 2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00343187 2011-05-30
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Allergan
Phase 2 Terminated